Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:EPZM
- CUSIP: N/A
- Web: www.epizyme.com
Capitalization:- Market Cap: $802.43 million
- Outstanding Shares: 58,358,000
Average Prices:- 50 Day Moving Avg: $14.87
- 200 Day Moving Avg: $13.82
- 52 Week Range: $7.02 - $18.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.80
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $7.53 million
- Price / Sales: 112.38
- Book Value: $2.99 per share
- Price / Book: 4.85
Profitability:- EBIDTA: ($120,070,000.00)
- Net Margins: -1,376.33%
- Return on Equity: -55.41%
- Return on Assets: -45.39%
Debt:- Current Ratio: 10.74%
- Quick Ratio: 10.74%
Misc:- Average Volume: 716,439 shs.
- Beta: 2.37
- Short Ratio: 14.02
Frequently Asked Questions for Epizyme (NASDAQ:EPZM)
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme, Inc. (NASDAQ:EPZM) released its quarterly earnings results on Monday, May, 8th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.07. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 55.41%. View Epizyme's Earnings History.
Where is Epizyme's stock going? Where will Epizyme's stock price be in 2017?
10 brokers have issued 1 year price objectives for Epizyme's shares. Their predictions range from $20.00 to $31.00. On average, they expect Epizyme's share price to reach $25.25 in the next year. View Analyst Ratings for Epizyme.
What are analysts saying about Epizyme stock?
Here are some recent quotes from research analysts about Epizyme stock:
- 1. Cann analysts commented, "Epizyme, Inc. announced today that the US Food and Drug Administration has granted Orphan Drug designation to Tazemetostat, for the treatment of patients with soft tissue sarcoma (STS). Management reported they are looking forward to continued engagement with FDA on Tazemetostat for rapid development in both solid tumors and hematological malignancies. Orphan Drug status for Tazemetostat supports our expectation that Epizyme could launch it in 2018. While the company has only guided to a goal of filing Tazemetostat with FDA by early 2018, we anticipate the drug could be approved and launched in the same year, due to the high unmet need in the settings where it is being developed: rare hematologic and solid tumor cancers." (6/21/2017)
- 2. Cowen and Company analysts commented, "Abstracts from ICML further support BGB-3111’s efficacy profile as being superior." (6/7/2017)
- 3. According to Zacks Investment Research, "Epizyme reported narrower-than-expected loss in the first quarter of 2017. In fact, the company’s efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth. Moreover, most of its candidates are in early stages of development and hence are several years away from commercialization." (5/22/2017)
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Array BioPharma (ARRY), BeiGene (BGNE), Acceleron Pharma (XLRN), Omeros Corporation (OMER), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Synergy Pharmaceuticals (SGYP), Xencor (XNCR), Achaogen (AKAO), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), ZIOPHARM Oncology (ZIOP), Coherus BioSciences (CHRS), NeuroDerm (NDRM), Ascendis Pharma A/S (ASND) and Aduro Biotech (ADRO).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Robert H. Bazemore Jr., President, Chief Executive Officer, Director
- Andrew E. Singer, Executive Vice President, Finance and Administration, Chief Financial Officer, and Treasurer
- Matthew Ros, Chief Operating Officer
- Robert A. Copeland Ph.D., Executive Vice President, Chief Scientific Officer
- Pamela Strode, Vice President - Regulatory Affairs and Quality Assurance
- Michael Boretti Ph.D., Vice President - Business Development
- Susan E. Graf, Chief Business Officer
- Peter Ho M.D., Ph.D., Chief Development Officer
- Andrew R. Allen M.D. Ph.D., Director
- Kevin T. Conroy, Director
Who owns Epizyme stock?
Epizyme's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.00%), Primecap Management Co. CA (11.23%), NEA Management Company LLC (10.75%), Palo Alto Investors LLC (8.21%), Vanguard Group Inc. (5.53%) and Jennison Associates LLC (3.32%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould. View Institutional Ownership Trends for Epizyme.
Who sold Epizyme stock? Who is selling Epizyme stock?
Epizyme's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Tekla Capital Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., SG Americas Securities LLC, Essex Investment Management Co. LLC and ProShare Advisors LLC. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.
Who bought Epizyme stock? Who is buying Epizyme stock?
Epizyme's stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Oracle Investment Management Inc., Vanguard Group Inc., Renaissance Technologies LLC, Foresite Capital Management III LLC, Iguana Healthcare Management LLC, Driehaus Capital Management LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.
How do I buy Epizyme stock?
Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of Epizyme stock can currently be purchased for approximately $14.50.
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Epizyme (NASDAQ:EPZM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $25.25 (74.14% upside) |
Analysts' Ratings History for Epizyme (NASDAQ:EPZM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/21/2017 | Cann | Reiterated Rating | Buy | $26.00 | Medium |  |
| 6/16/2017 | Leerink Swann | Reiterated Rating | Outperform | $31.00 | High | |
| 6/16/2017 | Citigroup Inc. | Boost Price Target | Buy | $20.00 -> $22.00 | Low | |
| 6/14/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $26.00 | High | |
| 6/12/2017 | Royal Bank Of Canada | Set Price Target | Buy | $20.00 | Low | |
| 6/7/2017 | Cowen and Company | Reiterated Rating | Buy | | High | |
| 6/7/2017 | HC Wainwright | Reiterated Rating | Buy | $25.00 | Medium | |
| 5/18/2017 | Wedbush | Reiterated Rating | Outperform | $24.00 | High | |
| 4/13/2017 | CIBC | Reiterated Rating | Outperform -> Outperform | | Low | |
| 11/6/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 6/20/2016 | Mizuho | Reiterated Rating | Buy | $18.00 | N/A | |
| 12/22/2015 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $21.00 | N/A | |
(Data available from 6/22/2015 forward)
Earnings History for Epizyme (NASDAQ:EPZM)Earnings History by Quarter for Epizyme (NASDAQ EPZM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($0.63) | ($0.56) | $0.49 million | | View | N/A | |
| 3/9/2017 | Q4 2016 | ($0.65) | ($0.60) | $0.61 million | $0.48 million | View | Listen | |
| 11/3/2016 | Q3 | ($0.60) | ($0.42) | $0.57 million | $6.58 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.52) | ($0.49) | $0.61 million | $0.47 million | View | Listen | |
| 5/9/2016 | Q1 | ($0.53) | ($0.41) | $0.58 million | $0.47 million | View | Listen | |
| 3/9/2016 | Q415 | ($0.65) | ($0.53) | $0.66 million | $0.56 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.59) | ($0.56) | $8.75 million | $0.36 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.70) | ($0.63) | $2.23 million | $0.74 million | View | Listen | |
| 4/28/2015 | Q115 | ($0.99) | ($1.75) | $6.48 million | $0.91 million | View | N/A | |
| 3/12/2015 | Q414 | ($0.54) | ($0.44) | $10.10 million | $10.35 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.54) | ($0.58) | $7.00 million | $8.20 million | View | N/A | |
| 8/13/2014 | Q214 | ($0.46) | ($0.40) | $7.59 million | $9.50 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.48) | ($0.22) | $7.67 million | $13.39 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.22) | $0.52 | $9.00 million | $36.32 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Epizyme (NASDAQ:EPZM)2017 EPS Consensus Estimate: ($2.60)
2018 EPS Consensus Estimate: ($2.09)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.65) | ($0.63) | ($0.64) |
| Q2 2017 | 4 | ($0.68) | ($0.41) | ($0.60) |
| Q3 2017 | 4 | ($0.74) | ($0.59) | ($0.67) |
| Q4 2017 | 4 | ($0.84) | ($0.55) | ($0.70) |
| Q1 2018 | 1 | ($0.54) | ($0.54) | ($0.54) |
| Q2 2018 | 1 | ($0.55) | ($0.55) | ($0.55) |
| Q3 2018 | 1 | ($0.54) | ($0.54) | ($0.54) |
| Q4 2018 | 1 | ($0.46) | ($0.46) | ($0.46) |
(Data provided by Zacks Investment Research)
Dividend History for Epizyme (NASDAQ:EPZM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Epizyme (NASDAQ:EPZM)Insider Ownership Percentage: 25.40%
Institutional Ownership Percentage: 81.18%
Insider Trades by Quarter for Epizyme (NASDAQ:EPZM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2017 | Robert A Copeland | Insider | Sell | 2,500 | $13.45 | $33,625.00 | |
| 5/25/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.11 | $241,650.00 | |
| 5/2/2017 | Robert A Copeland | Insider | Sell | 5,000 | $17.44 | $87,200.00 | |
| 4/4/2017 | Robert A Copeland | Insider | Sell | 5,000 | $16.36 | $81,800.00 | |
| 3/31/2017 | Andrew E Singer | CFO | Sell | 2,013 | $17.09 | $34,402.17 | |
| 1/9/2017 | Andrew E Singer | CFO | Sell | 1,013 | $12.04 | $12,196.52 | |
| 12/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $11.03 | $11,173.39 | |
| 11/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.40 | $10,535.20 | |
| 10/10/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.72 | $9,846.36 | |
| 9/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $7.55 | $7,648.15 | |
| 8/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.05 | $9,167.65 | |
| 8/1/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.37 | $41,480.00 | |
| 7/11/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.36 | $10,494.68 | |
| 7/5/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.03 | $40,120.00 | |
| 6/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.49 | $12,652.37 | |
| 4/12/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.42 | $12,581.46 | |
| 3/9/2016 | Andrew E Singer | CFO | Sell | 1,006 | $9.33 | $9,385.98 | |
| 2/29/2016 | Peter Tai-Ching Ho | Insider | Buy | 636 | $7.47 | $4,750.92 | |
| 2/10/2016 | Andrew E. Singer | CFO | Sell | 12,158 | $9.54 | $115,987.32 | |
| 1/12/2016 | Bay City Capital Fund V Co-Inv | Major Shareholder | Buy | 555,555 | $9.00 | $4,999,995.00 | |
| 1/12/2016 | David M Mott | Director | Buy | 1,111,111 | $9.00 | $9,999,999.00 | |
| 1/4/2016 | Robert A. Copeland | insider | Sell | 4,185 | $15.58 | $65,202.30 | |
| 12/30/2015 | Robert J. Gould | Director | Sell | 32,108 | $18.01 | $578,265.08 | |
| 12/9/2015 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $14.69 | $14,690.00 | |
| 12/7/2015 | Robert A. Copeland | insider | Sell | 4,185 | $13.82 | $57,836.70 | |
| 11/9/2015 | Robert A. Copeland | insider | Sell | 4,185 | $16.26 | $68,048.10 | |
| 10/5/2015 | Robert A. Copeland | insider | Sell | 4,185 | $14.43 | $60,389.55 | |
| 9/8/2015 | Robert A. Copeland | insider | Sell | 4,185 | $19.58 | $81,942.30 | |
| 9/8/2015 | Robert J. Gould | CEO | Sell | 60,000 | $19.86 | $1,191,600.00 | |
| 7/6/2015 | Robert A Copeland | Insider | Sell | 8,371 | $22.86 | $191,361.06 | |
| 7/6/2015 | Robert J Gould | CEO | Sell | 60,000 | $23.22 | $1,393,200.00 | |
| 5/5/2015 | Peter Tai-Ching Ho | Insider | Buy | 800 | $16.36 | $13,088.00 | |
| 12/2/2014 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $21.17 | $21,170.00 | |
| 11/17/2014 | Robert A Copeland | EVP | Sell | 20,000 | $22.68 | $453,600.00 | |
| 11/3/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.47 | $509,400.00 | |
| 11/3/2014 | Robert J Gould | CEO | Sell | 30,000 | $24.95 | $748,500.00 | |
| 10/7/2014 | Robert A Copeland | EVP | Sell | 20,000 | $26.90 | $538,000.00 | |
| 10/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $26.28 | $788,400.00 | |
| 10/1/2014 | Stephen Garbacz | Insider | Sell | 868 | $27.06 | $23,488.08 | |
| 9/22/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.55 | $511,000.00 | |
| 9/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $28.67 | $57,340.00 | |
| 9/4/2014 | Carl Goldfischer | Director | Sell | 4,000 | $35.14 | $140,560.00 | |
| 8/26/2014 | Bay City Capital Llc | Major Shareholder | Sell | 200,000 | $35.14 | $7,028,000.00 | |
| 8/25/2014 | Bay City Capital Llc | Major Shareholder | Sell | 366,666 | $33.98 | $12,459,310.68 | |
| 8/18/2014 | Robert A Copeland | EVP | Sell | 10,830 | $36.07 | $390,638.10 | |
| 8/15/2014 | Ryan D Drant | Major Shareholder | Sell | 4,061 | $36.54 | $148,388.94 | |
| 8/4/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $29.74 | $892,200.00 | |
| 8/4/2014 | Robert A Copeland | EVP | Sell | 20,000 | $29.42 | $588,400.00 | |
| 7/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $31.35 | $62,700.00 | |
| 7/7/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $32.74 | $982,200.00 | |
| 7/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $31.53 | $945,900.00 | |
| 6/23/2014 | Robert A Copeland | EVP | Sell | 20,000 | $28.42 | $568,400.00 | |
| 6/16/2014 | Eric Hedrick | Insider | Sell | 2,000 | $26.42 | $52,840.00 | |
| 6/16/2014 | Robert A Copeland | EVP | Sell | 25,012 | $26.38 | $659,816.56 | |
| 6/2/2014 | Robert J Gould | CEO | Sell | 30,000 | $22.20 | $666,000.00 | |
| 5/19/2014 | Robert Copeland | EVP | Sell | 5,000 | $22.28 | $111,400.00 | |
| 5/5/2014 | Jason Rhodes | CFO | Sell | 30,000 | $21.53 | $645,900.00 | |
| 5/5/2014 | Robert Copeland | EVP | Sell | 10,000 | $21.29 | $212,900.00 | |
| 5/1/2014 | Robert Gould | CEO | Sell | 30,000 | $21.91 | $657,300.00 | |
| 4/28/2014 | Robert Copeland | EVP | Sell | 13,800 | $20.73 | $286,074.00 | |
| 4/7/2014 | Jason Rhodes | CFO | Sell | 25,000 | $20.05 | $501,250.00 | |
| 4/7/2014 | Robert Gould | CEO | Sell | 30,000 | $20.22 | $606,600.00 | |
| 2/10/2014 | Celgene European Investment Co | major shareholder | Buy | 340,000 | $29.25 | $9,945,000.00 | |
| 1/6/2014 | Jason Rhodes | CFO | Sell | 10,000 | $20.19 | $201,900.00 | |
| 12/16/2013 | Robert Copeland | EVP | Sell | 4,600 | $21.21 | $97,566.00 | |
| 12/2/2013 | Robert Copeland | EVP | Sell | 5,000 | $20.70 | $103,500.00 | |
| 11/15/2013 | M James Barrett | major shareholder | Buy | 406,500 | $19.68 | $7,999,920.00 | |
| 6/5/2013 | David M Mott | Director | Buy | 400,000 | $15.00 | $6,000,000.00 | |
| 6/5/2013 | Venture Fund I L.P. Astellas | Major Shareholder | Buy | 15,333 | $15.00 | $229,995.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Epizyme (NASDAQ:EPZM)
Latest Headlines for Epizyme (NASDAQ:EPZM)
| Source: |
|
| Date | Headline |
|---|
 | Biotech Movers: Sangamo, Epizyme, Revance - TheStreet.com
www.thestreet.com - June 21 at 6:32 PM |
 | Biotech Movers: Sangamo, Epizyme, Revance
finance.yahoo.com - June 21 at 6:32 PM |
| Biotech Movers: AveXis, Clovis, Epizyme - TheStreet.com
www.thestreet.com - June 20 at 10:46 PM |
 | FY2017 EPS Estimates for Epizyme, Inc. (EPZM) Lifted by Analyst
www.americanbankingnews.com - June 19 at 7:20 AM |
| Epizyme (EPZM) Jumps: Stock Rises 17.4%
finance.yahoo.com - June 16 at 3:18 PM |
| Leerink Swann Reiterates "Outperform" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - June 16 at 12:34 PM |
| Citigroup Inc. Reiterates "Buy" Rating for Epizyme, Inc. (EPZM)
www.americanbankingnews.com - June 16 at 11:52 AM |
| FY2018 EPS Estimates for Epizyme, Inc. (EPZM) Lifted by Analyst
www.americanbankingnews.com - June 16 at 11:24 AM |
| Why Epizyme Inc.'s Shares Are Skyrocketing Today
finance.yahoo.com - June 16 at 12:06 AM |
| Epizyme, Inc. (EPZM) Given a $26.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 15 at 11:20 PM |
| Epizyme Provides Positive Interim Data on EZH2 Inhibitor
finance.yahoo.com - June 15 at 7:06 PM |
| Why Epizyme, Tribune Media, and Revlon Jumped Today
finance.yahoo.com - June 15 at 7:06 PM |
 | Epizyme (EPZM) Announces Positive Interim Data from Phase 2 Trial for Tazemetostat in R/R Follicular Lymphoma and DLBCL Patients
www.streetinsider.com - June 15 at 4:09 AM |
| Epizyme (EPZM) Announces Positive Interim Data from Phase 2 Trial for Tazemetostat in R/R Follicular Lymphoma and ... - StreetInsider.com
www.streetinsider.com - June 14 at 11:07 PM |
| Pre-Open Stock Movers 06/14: (BKD) (HRB) (RDHL) Higher; (ALDX) (EPZM) (HA) Lower (more...)
www.streetinsider.com - June 14 at 6:07 PM |
| Epizyme Inc (EPZM) Ends Positive After a Rollercoaster Ride; Oppenheimer Weighs in
finance.yahoo.com - June 14 at 6:07 PM |
 | Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients
feeds.benzinga.com - June 14 at 9:22 AM |
| Epizyme, Inc. (EPZM) Given a $20.00 Price Target by Royal Bank Of Canada Analysts
www.americanbankingnews.com - June 13 at 5:18 PM |
| Epizyme (EPZM) Down 19.2% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 11:58 AM |
| Epizyme Inc (EPZM) Expected to Announce Quarterly Sales of $2.89 Million
www.americanbankingnews.com - June 10 at 9:02 AM |
| Epizyme Inc (EPZM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 9 at 11:22 AM |
| Zacks: Analysts Expect Epizyme Inc (EPZM) to Post -$0.60 Earnings Per Share
www.americanbankingnews.com - June 8 at 12:24 PM |
| Epizyme Inc (EPZM) Given Buy Rating at Cowen and Company
www.americanbankingnews.com - June 7 at 9:44 PM |
| Epizyme Inc (EPZM) Insider Robert A. Copeland Sells 2,500 Shares
www.americanbankingnews.com - June 7 at 4:48 PM |
| HC Wainwright Reiterates Buy Rating for Epizyme Inc (EPZM)
www.americanbankingnews.com - June 7 at 1:36 PM |
| Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data
finance.yahoo.com - June 5 at 5:06 PM |
| Oppenheimer Holdings Inc. Analysts Give Epizyme Inc (EPZM) a $26.00 Price Target
www.americanbankingnews.com - June 5 at 2:26 PM |
| Epizyme Inc (EPZM) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - June 3 at 4:28 PM |
| Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 26, 2017
finance.yahoo.com - May 26 at 5:38 PM |
| Insider Selling: Epizyme Inc (EPZM) Insider Sells 15,000 Shares of Stock
www.americanbankingnews.com - May 26 at 1:35 PM |
| Epizyme Inc (EPZM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 22 at 3:14 PM |
| Epizyme Inc to Post FY2018 Earnings of ($2.95) Per Share, SunTrust Banks Forecasts (EPZM)
www.americanbankingnews.com - May 22 at 8:50 AM |
| Equities Analysts Offer Predictions for Epizyme Inc's Q1 2018 Earnings (EPZM)
www.americanbankingnews.com - May 22 at 7:30 AM |
| Epizyme Inc (EPZM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 19 at 11:34 AM |
| Epizyme (EPZM) Identifies Path Toward Submission for Accelerated ... - StreetInsider.com
www.streetinsider.com - May 19 at 5:02 AM |
| Epizyme's (EPZM) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - May 18 at 4:40 PM |
| Implied Volatility Surging for Epizyme (EPZM) Stock Options
finance.yahoo.com - May 18 at 10:22 AM |
| Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
finance.yahoo.com - May 17 at 10:56 AM |
| Epizyme Inc (EPZM) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 6:58 PM |
| Epizyme Inc (EPZM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 12:08 PM |
| Zacks: Brokerages Anticipate Epizyme Inc (EPZM) Will Announce Quarterly Sales of $520,000.00
www.americanbankingnews.com - May 14 at 10:04 AM |
| -$0.60 EPS Expected for Epizyme Inc (EPZM) This Quarter
www.americanbankingnews.com - May 12 at 12:30 PM |
| Epizyme Inc (EPZM) to Post Q2 2017 Earnings of ($0.68) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 11 at 8:50 AM |
| Epizyme Inc to Post Q2 2017 Earnings of ($0.66) Per Share, Oppenheimer Holdings Forecasts (EPZM)
www.americanbankingnews.com - May 11 at 8:50 AM |
| Q2 2017 Earnings Forecast for Epizyme Inc (EPZM) Issued By Wedbush
www.americanbankingnews.com - May 11 at 8:48 AM |
| Today's Research Reports on Stocks to Watch: Insys Therapeutics and Epizyme
finance.yahoo.com - May 10 at 5:08 PM |
| FY2020 EPS Estimates for Epizyme Inc (EPZM) Cut by Analyst
www.americanbankingnews.com - May 10 at 3:38 PM |
| Brokers Issue Forecasts for Epizyme Inc's FY2017 Earnings (EPZM)
www.americanbankingnews.com - May 10 at 10:00 AM |
| Royal Bank of Canada Reiterates "Buy" Rating for Epizyme Inc (EPZM)
www.americanbankingnews.com - May 10 at 7:38 AM |
| Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 9, 2017
finance.yahoo.com - May 9 at 4:57 PM |
Epizyme (EPZM) Chart for Thursday, June, 22, 2017
